During the corresponding time, 2seventy Bio Inc recorded a revenue increase by 84.46 % year on year, sequentially revenue grew by 683.94 %. While revenue at the 2seventy Bio Inc 's corporate clients
In a year marked by resilience and strategic refocusing, 2seventy bio, Inc. (Nasdaq: TSVT), has made significant strides in its efforts to establish a robust foothold within the biopharmaceutical industry. From achieving impressive sales results for its CAR-T therapy, Abecma, to the sale of its Hemophilia A candidate and gene editing technologies to Novo Nordisk, the company is poised for a promising future. Abecma Sales PerformanceIn its recent report, 2seventy bio announced the full-year U.S. sales results for Abecma (idecabtagene vicleucel; ide-cel), in collaboration with Bristol Myers Squibb (BMS). The company recorded U.S. revenue of $242 million for 2024, landing comfortably within its guidance range o...
CSIMarket.com : Edition September 27, 2024 Investigation Launched into 2seventy bio, Inc.: Investors Urged to Collaborate NEW YORK The renowned legal establishment of Bronstein, Gewirtz, and Grossman, LLC, hath declared an undertaking of an inquiry concerning potential grievances associated with the acquisitions of securities from 2seventy bio, Inc. (henceforth referred to as 2seventy bio or the Company), registered under the ticker NASDAQ: TSVT. This announcement, made on the 27th of September in the year 2024, seeks the assistance and cooperation of those individuals and entities who have partaken in the procurement of securities issued by the aforementioned Company. The esteemed firm urges these inve...
In a compelling display of corporate metamorphosis, 2seventy bio, Inc. (NASDAQ: TSVT) has unveiled its financial results for Q2 2024, which depict a rollercoaster journey marked by both extraordinary growth and the specter of short-term challenges. The biopharmaceutical company, based in Cambridge, Massachusetts, signaled its significant transformation under CEO Chip Baird, who characterized this year as one of profound operational evolution.The numbers tell a compelling story. Remarkably, 2seventy bio achieved a year-on-year revenue increase of 167.38%, a statistic that underlines the company’s ability to capitalize on market opportunities and demonstrates a robust demand for its innovative therapies. Suc...
In a recent development, Novo Nordisk has completed the acquisition of 2seventy bio, Inc. s Hemophilia A program and the rights to their in vivo gene editing technology (excluding oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease). This sale marks an important milestone for both companies within the field of pharmaceutical sciences.Details of the Acquisition:Under the terms of the asset purchase agreement (APA), Novo Nordisk has successfully acquired the Hemophilia A program as well as the rights to 2seventy bio s in vivo gene editing technology. This acquisition is of significant value to Novo Nordisk, as it enables them to expand t...
Sources:
2seventy Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: 2seventy Bio Inc’s corporate clients.
For your research, we’ve provided 9 tables on 2seventy Bio Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
79.07 %